Health Condition 1: null- Coronary artery disease
Conditions
Interventions
Intervention1: Standardized aqueous extract of Terminalia arjuna: Oral Administration 500mg BD twice a day.
Control Intervention1: Placebo: Oral Administration 500mg BD twice a day
Sponsors
Director PGIMER Chandigarh
The Himalaya Drug Company
Eligibility
Inclusion criteria
Inclusion criteria: Non-diabetic patients with stable coronary artery disease having disease more than 3 months or more prior to the enrolment and were using any combination of cardiac related medications including ASA, ACEIs, Beta-Blockers and statins were enrolled in the present study during their follow-up visit to cardiology clinic at Advance Cardiac centre, PGIMER, Chandigarh. Patients who gave prior written consent were only enrolled in the study
Exclusion criteria
Exclusion criteria: Subjects with diabetes, Chronic liver disease, Chronic Renal failure or any other inflammatory or infectious disease were excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of Inflammatory markers assessed by gene expression studies in two groups i.e. Drug Treated vs Placebo at baseline (Before Terminalia arjuna treatment), 3 and 6 Months (During TA Treatment)Timepoint: Baseline (Before Terminalia arjuna Treatment), At 3 and 6 Months (During Terminalia arjuna treatment). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Clinical safety and efficacy through MACCE. 2. Clinical Improvement in the form of symptoms 3. Improvement in lipid and lipoprotein profile 4. Reduction in inflammatory markersTimepoint: At Baseline (Before Terminalia arjuna Treatment), At 3 and 6 Months (During Terminalia arjuna treatment). | — |
Countries
India
Contacts
Public ContactVeena Dhawan
PGIMER
Outcome results
None listed